Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients

BACKGROUND: Sodium–glucose co-transporter 2 (SGLT2) inhibitors provide cardiovascular protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However, there is little evidence of their application in patients with chronic kidney disease (CKD). Furthermore, there are inco...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiutian, Wang, Jiali, Lin, Yongda, Yao, Kaijin, Xie, Yina, Zhou, Tianbiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690412/
https://www.ncbi.nlm.nih.gov/pubmed/38047108
http://dx.doi.org/10.3389/fendo.2023.1236404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690412/
https://www.ncbi.nlm.nih.gov/pubmed/38047108
http://dx.doi.org/10.3389/fendo.2023.1236404

Ejemplares similares